SELLAS Life Sciences Group, Inc.
SLSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. Valued at $2.59B, SLS is a mid-cap name in its sector. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Market Cap
$2.59B
Beta
2.42
P/E (TTM)
—
P/E (Fwd)
-105.52
EPS (TTM)
$-0.26
EPS (Fwd)
$-0.13
ROE
-43.6%
ROA
-25.4%
Cash
$107.1M
Total Debt
$871,000
Free CF
-$17.7M
52W Change
645.2%
Annual Financials
Cash vs Debt
SELLAS Life Sciences Group, Inc. holds $107.1M in cash against $871K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$17.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -43.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.0M (2022) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, SLS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SLS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.